IMOVAX D.T. ADULT 0.5 ml Suspension for injection in pre-filled syringe

As with all vaccines administered by injection, appropriate medical treatment and supervision should always be available in case of an anaphylactic reaction following administration of the vaccine. Immunosuppressive therapy or immunodeficiency may induce a decreased immune response to vaccination. It is therefore recommended to vaccinate after completion of treatment or to ensure that the individual is adequately protected. Nevertheless, vaccination of individuals with chronic immunosuppression, such as HIV infection, is recommended if the underlying disease permits an immune response, even if limited. To prevent hypersensitivity reactions, the vaccine should not be administered to individuals who have been vaccinated according to the primary vaccination schedule or received a booster within the last 5 years. If Guillain-Barré syndrome or brachial neuritis occurred following previous administration of a vaccine containing tetanus toxoid, the potential benefits and possible risks should be carefully considered before administering any vaccine containing tetanus toxoid. Vaccination is usually justified when the primary vaccination schedule has not been completed (i.e. fewer than three doses have been administered). Do not administer intravascularly. Ensure that the needle has not penetrated a blood vessel. Syncope may occur following or even before any vaccination as a psychogenic response to injection with a needle. Appropriate procedures should be in place to prevent falls and injuries resulting from syncope. Imovax D.T. Adult (Td) contains less than 1 mmol of potassium (39 mg) and less than 1 mmol of sodium (23 mg) per dose, i.e. essentially negligible amounts of potassium and sodium. Traceability To improve traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.